Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
116 studies found for:    MAST CELL DISEASE
Show Display Options
Rank Status Study
21 Completed Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
Conditions: Mastocytosis;   Anaphylaxis
Intervention:
22 Completed Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
Conditions: Leukemia;   Systemic Mastocytosis
Intervention: Drug: Ontak (Denileukin Diftitox)
23 Recruiting A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
Condition: Indolent Systemic Mastocytosis
Intervention: Drug: AK002
24 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Intervention: Drug: brentuximab vedotin
25 Not yet recruiting Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations
Conditions: Urticaria Pigmentosa;   Cutaneous Mastocytosis
Interventions: Other: skin biopsy;   Other: blood draw
26 Recruiting Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
Conditions: Aggressive Systemic Mastocytosis (ASM);   Systemic Mastocytosis With Associated Clonal Hematological Non-mast Cell Lineage Disease (SM-AHNMD);   Mast Cell Leukemia (MCL);   Smoldering Systemic Mastocytosis (SSM);   Indolent Systemic Mastocytosis (ISM) [ISM Subgroup Fully Recruited]
Intervention: Other: Interview
27 Unknown  A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap
Conditions: Smouldering Systemic Mastocytosis;   Indolent Systemic Mastocytosis;   Cutaneous Mastocytosis With Handicap;   Mastocytosis
Interventions: Drug: masitinib (AB1010);   Drug: placebo
28 Recruiting Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis;   Associated Clonal Hematological Non-Mast-Cell Lineage Disease
Interventions: Drug: Ibrutinib;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
29 Completed Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals
Conditions: Atopic Dermatitis;   Healthy;   Mastocytosis
Intervention:
30 Recruiting Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
Conditions: Aggressive Systemic Mastocytosis;   Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease;   Mast Cell Leukemia;   Relapsed or Refractory Myeloid Malignancies
Intervention: Drug: BLU-285
31 Recruiting Study of Factors Regulating Mast Cell Proliferation
Condition: Mastocytosis
Intervention:
32 Active, not recruiting
Has Results
Phase II Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Conditions: Systemic Mastocytosis, Aggressive (ASM);   Leukemia, Mast Cell;   Hematological Non-mast Cell Lineage Disease (AHNMD)
Intervention: Drug: Midostaurin
33 Unknown  Clonal Mast Cell Disorders in Exercise-Induced Anaphylaxis
Condition: Anaphylaxis
Intervention:
34 Completed Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
Conditions: Non Neoplastic Condition;   Precancerous Condition
Intervention: Drug: thalidomide
35 Recruiting SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)
Conditions: Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Advanced Systemic Mastocytosis;   Advanced Symptomatic Primary Eosinophilic Disorder
Intervention: Drug: SL-401
36 Recruiting Study of Mast Cell Precursors
Conditions: Normal Physiology;   Systemic Mastocytosis
Intervention:
37 Completed Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
Conditions: Chronic Myelomonocytic Leukemia;   Chronic Myeloid Leukemia;   Polycythemia Vera;   Hypereosinophilic Syndrome;   Mastocytosis
Intervention: Drug: Imatinib Mesylate (Gleevec)
38 Active, not recruiting Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
Condition: Leukemia
Intervention: Drug: Midostaurin
39 Completed 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Nonneoplastic Condition;   Precancerous Condition
Intervention: Drug: tanespimycin
40 Recruiting A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Conditions: Gastrointestinal Stromal Tumors;   Aggressive Systemic Mastocytosis;   Advanced Cancers
Intervention: Drug: DCC-2618

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.